Dopamine receptor topography. Characterization of antagonist requirements of striatal dopamine-sensitive adenylate cyclase using protoberberine alkaloids

Inhibitory effect of berberine on the motivational effects of ethanol in mice

It is believed that drug-induced rewarding effects play an important role in the development of substance dependence. Recently, berberine was reported to inhibit the rewarding effects of drugs of abuse such as cocaine, morphine, and nicotine. Berberine is also demonstrated to modulate the activity of several neurotransmitter systems like, dopamine, nitric oxide, serotonin, and NMDA, which are implicated in rewarding effects of ethanol. Hence, we hypothesized that berberine may modulate the ethanol-induced rewarding effects. Therefore, we studied the effect of berberine on locomotor sensitization, conditioned place preference (CPP), and ethanol drinking preference in mice. The results revealed that acute administration of berberine (2.5, 5, and 10 mg/kg, i.p.) dose dependently reduced locomotor stimulant effect of acute ethanol and expression of sensitization to locomotor stimulant effect of ethanol. Further, pretreatment with berberine (2.5, 5, and 10 mg/kg, i.p.) prior to each dose of ethanol, blocked the development as well as expression of sensitization to locomotor stimulant effect of ethanol. In another set of experiment, treatment with berberine (5 and 10 mg/kg, i.p.) reduced the induction and expression of ethanol-induced CPP in mice. In addition, berberine in these doses also reduced preference to ethanol drinking over water, but did not alter the general reward. In conclusion, the results of the present study revealed that berberine attenuates ethanol-induced rewarding effects in mice and that could be attributed to its neuro-modulatory action.

Coptidis Rhizoma attenuates repeated nicotine-induced behavioural sensitization in the rat

Repeated injections of nicotine can produce an increase in locomotor activity and the expression of immediate-early gene, c-fos, in the central dopaminergic areas. Many studies have shown that Coptidis Rhizoma (CR) and its main alkaloid compound, berberine (BER), have a suppressive effect on the central nervous system. We examined the influence of CR or BER on repeated nicotine-induced locomotor activity in rats and the change of c-Fos expression in the brain by using immunohistochemistry. Male Sprague-Dawley rats were given CR and BER before repeated injections of nicotine hydrochloride (0.4 mg kg−1, s.c.) twice daily for 7 days. After 3 days withdrawal, rats received a challenge injection of nicotine. Pretreatment with CR (100 mg kg−1, i.p.) and BER (100 mg kg−1, i.p.) significantly inhibited the nicotine-induced locomotor activity and expression of c-Fos in the striatum and the nucleus accumbens. These results suggest that CR and BER may produce inhibitory effects of nicotine on behavioural sensitization by possibly reducing postsynaptic neuronal activation in the central dopaminergic systems.

Inhibitory Effects of Coptidis rhizoma and Berberine on Cocaine-induced Sensitization

Substantial evidence suggests that the behavioral and reinforcing effects of cocaine can be mediated by the central dopaminergic systems. Repeated injections of cocaine produce an increase in locomotor activity and the expression of tyrosine hydroxylase (TH) in the main dopaminergic areas. Protoberberine alkaloids affect neuronal functions. Coptidis rhizoma (CR) and its main compound, berberine (BER) reduced the dopamine content in the central nervous system. In order to investigate the effects of CR or BER on the repeated cocaine-induced neuronal and behavioral alterations, we examined the influence of CR or BER on the repeated cocaine-induced locomotor activity and the expression of TH in the brain by using immunohistochemistry. Male SD rats were given repeated injections of saline or cocaine hydrochloride (15 mg/kg, i.p. for 10 consecutive days) followed by one challenge injection on the 4th day after the last daily injection. Cocaine challenge (15 mg/kg, i.p) produced a larger increase in locomotor activity and expression of TH in the central dopaminergic areas. Pretreatment with CR (50, 100, 200 and 400 mg/kg, p.o.) and BER (200 mg/kg, p.o.) 30 min before the daily injections of cocaine significantly inhibited the cocaine-induced locomotor activity as well as TH expression in the central dopaminergic areas. Our data demonstrate that the inhibitory effects of CR and BER on the repeated cocaine-induced locomotor activity were closely associated with the reduction of dopamine biosynthesis and post-synaptic neuronal activity. These results suggest that CR and BER may be effective for inhibiting the behavioral effects of cocaine by possibly modulating the central dopaminergic system.

Striatally-mediated response of some structurally rigid analogues of dopamine

The potency of structurally rigid analogues of dopamine (DA) at striatal dopamine receptors was evaluated in rats using three types of assessments: (a) effectiveness in producing rotational and sniffing behaviors by intrastriatal injections (b) inhibition of [3H]-spiroperidol binding and (c) stimulation of adenylate cyclase activity. The compounds included apomorphine (APO) and its analogues, (R)-2,10,11-trihydroxyaporphine (R-THA) and (R)-2-hydroxy-10,11-methylenedioxyaporphine (MDO-APO), 2-amino-6,7-dihydroxyaminotetraline (ADTN) and its analogue, exo-2-amino-6,7-dihydroxybenzonorbornene (exo-amine). (R)-THA produced no stereotypy yet it was a potent inhibitor of [3H]-spiroperidol binding and adenylate cyclase activity. MDO-APO was quite active in inducing stereotypy and stimulating cyclase activity, but it showed low potency in displacing [3H]-spiroperidol. The exo-amine and ADTN were equally potent in enhancing rotation and sniffing intensity, however, the former was completely inactive in biochemical assessments. Except for (R)-THA, all DA analogues studied elicited dopaminomimetic behavioral activities of circling and sniffing. Relationships between the actions of these drugs in the behavioral and biochemical assessments are discussed.

Effects of several ergosines on adenylate cyclase activity in synaptosomal membranes of the bovine caudate nucleus

The effects of several ergosines and different dopamine agonists and antagonists on the activity of dopamine-sensitive adenylate cyclase in synaptosomal membranes of the bovine caudate nucleus were comparatively studied. Among ergot alkaloid derivatives used, ergosinine was the most active in stimulating adenylate cyclase activity. Ergosine, bromoergosine, dihydroergosine, dihydroergocryptine and lisuride also stimulated this enzyme. Dihydroergosinine, bromodihydroergosine and bromoergocryptine did not affect adenylate cyclase activity. Saccharino derivatives of both ergosine and ergosinine were inactive. When used in higher concentrations, ergosine, ergosinine, dihydroergocryptine and lisuride inhibited dopamine-stimulated adenylate cyclase whereas other ergot alkaloid derivatives examined did not. If the extent of dopamine-sensitive adenylate cyclase stimulation is considered as a measure of dopaminergic activity, examination of the structure/dopaminergic activity relationship showed that modifications of ergot alkaloid molecules such as isomerization in position 8, hydrogenation of delta 9(10)-double bond, or introduction of bromine into position 2 of the molecule, lead to a significant decrease of stimulatory effects of adenylate cyclase. Introduction of a saccharino group into position 2 of the molecule caused a total loss of stimulatory activity of both ergosine and ergosinine, probably because of the size of the saccharino residue.

Regioselective O-methylation of tetrahydropapaveroline and tetrahydroxyberbine in vivo in rat brain

Enzymatic O-methylation is a primary pathway for the metabolism of catecholamines in mammals and of isoquinoline alkaloids in plants. This report describes the differential O-methylation patterns of the racemates and enantiomers of two catecholamine-derived alkaloids, tetrahydropapaveroline (THP) and 2,3,10,11-tetrahydroxyberbine (THB), in the brain of the rat. One hour after intracerebroventricular administration of a specific isomeric form of each alkaloid, the O-methylated metabolites were isolated from the rat brain and subsequently quantified using high performance liquid chromatography. The isomeric form of THP or THB which was administered markedly influenced the pattern of O-methylation. The racemate and R-(+)-enantiomer of THP were mono-O-methylated predominantly at the 7 and 3' positions, while the S-(-)-enantiomer of THP was mono-O-methylated to an essentially equal degree at the 6, 7 and 3' positions. Minimal mono-O-methylation at the 4' position was detectable only with the racemate and (-)-enantiomer of THP. The racemate and enantiomers of THB were mono-O-methylated predominantly at the 2 and 11 positions and to a lesser extent at the 3 and 10 positions. Although minimal with the R-(+)-enantiomer, the 3 and the 10-O-methylation pathways were enhanced significantly with the S-(-)-enantiomer of THB. These results demonstrate that both enantiomers of THP and THB are O-methylated in vivo in rat brain and that the chiral centers of these alkaloids influence the position of O-methylation, thereby dictating the relative amounts of specific products formed.

Multiple dopamine receptors and behavior

The therapeutic effects of dopamine (DA) agonists and DA antagonists used in the treatment of schizophrenia (antipsychotics, DA antagonists), Huntington's chorea (DA antagonists) and Parkinson's disease (antiparkinsonian agents, DA agonists) have been thought to result largely from actions on DA receptors located in the striatum (caudate nucleus and putamen). Many of the classical drugs used to treat these disorders are known to have a high incidence of extrapyramidal side effects (EPS). However, a number of drugs, the atypical antipsychotics and antiparkinsonian agents, have been developed which have a low incidence of EPS. It has been of enormous interest to researchers and clinicians alike to determine what characteristics of the atypical antipsychotics and antiparkinsonian agents are responsible for their unique behavioral profile. Because all of the antipsychotics and antiparkinsonian agents act on DA receptors, much attention has focused on potential differences in the interactions of the atypical agents with DA receptors. An hypothesis that has been raised, due to the knowledge that there are multiple subtypes of DA receptors located in the striatum, is that the atypical agents could have their therapeutic actions as a result of an interaction with one specific subtype of DA receptor. This review emphasizes two major points: (1) it is unlikely that the atypical antipsychotics and antiparkinsonian agents interact with only one subtype of DA receptor, or have their therapeutic actions only through that receptor; (2) other pharmacological characteristics of these agents are more critically involved in their unique behavioral effects. The applicability of animal models to assess the pharmacological and behavioral profiles of these agents is discussed, and the relevance to the clinical profiles of these agents is emphasized.

Interaction of catecholamine-derived alkaloids with central neurotransmitter receptors

Catecholamine-derived alkaloids of the simple tetrahydroisoquinoline, 1-benzyl-tetrahydroisoquinoline and tetrahydroprotoberberine classes have been tested for their ability to inhibit the binding of seven different radioligands to neurotransmitter receptors of brain synaptic membranes. Alkaloids of all three classes were active in inhibiting 3H-clonidine binding to alpha 2-adrenergic receptors. Stereoselectivity of tetrahydropapaveroline in binding to alpha 2-adrenergic receptors was evidenced by the marked activity of the S-(--) isomer (IC50 = 0.65 microM) in comparison to the R-(+) enantiomer (IC50 = 50 microM). The simple tetrahydroisoquinolines (3,4-dihydroxytetrahydroisoquinoline and salsolinol), the four isomeric mono-O-methyl derivatives of 2,3,10,11-tetrahydroxyberbine and tetrahydropapaveroline were the most potent inhibitors of 3H-apomorphine binding to dopaminergic receptor agonist sites. The tetrahydroprotoberberines, as a class, were the most potent inhibitors of 3H-spiroperidol binding to dopaminergic receptor antagonist sites and of 3H-WB-4101 binding to alpha 1-adrenergic receptors. The 1-benzyl-tetrahydroisoquinolines exhibited varying degrees of interaction with beta 1-adrenergic receptors. Tetrahydropapaveroline (IC50 = 0.3 microM) was the most active of the 24 alkaloids tested in inhibiting binding of 3H-dihydroalprenolol to beta 1-adrenergic receptors. None of the alkaloids significantly affected 3H-QNB binding to muscarinic-cholinergic receptors, and selected alkaloids from each class interacted only moderately with serotonergic receptors.

The route and significance of endogenous synthesis of alkaloids in animals

There is now substantial evidence that several TIQs and beta-carbolines are present in vivo and increase during certain pathological conditions. It still remains to be determined, however, precisely what roles they play in endogenous functions and whether or not they are critical for the expression of these pathological conditions. Accumulating biochemical information continues to support the notion that these compounds can act as false transmitters. The exciting new findings, which will certainly receive a great deal more attention, concern the interaction of some of the beta-carbolines with the benzodiazepine receptor. Determining if a beta-carboline is an endogenous receptor ligand will attract further research interest on the theoretical and specifically clinically-directed levels. Biochemical, morphological, and behavioral data indicate that some of the condensation products can act as neurotoxins. Very few experiments have included an examination of long-term effects of exposure to one of these alkaloids, so the amount of information on this issue is limited. Chronic rather than acute administration of an alkaloid is more likely to mimic the pathological states in which these compounds are hypothesized to play a role. Biochemically, both the dopaminergic and serotonergic systems have been shown to be affected by chronic treatments with certain alkaloids. Progressive and long-term behavioral alterations also have been reported. Such changes may reflect an adaptation to an increase or decrease in activity of particular systems or a neurotoxic action.

A critical evaluation of tetrahydroisoquinoline induced ethanol preference in rats

It has been reported that certain tetrahydroisoquinoline compounds, especially salsolinol and tetrahydropaveroline (THP) when infused into the lateral ventricle of rats' brains results in increased preference for alcohol solutions. The effect is reported to be long-term, in that animals do not return to baseline drinking even months later. The current report provides a replicatin of the original experiments and also an extension of the work to complete dose-response curves for salsolinol and THP. Generally we have confirmed that rats of the Sprague-Dawley and Long-Evans strains do increase their alcohol intake in response to infused THP or salsolinol and that the effect is long lasting, up to 10 months. Such animals consume less alcohol at concentrations above 20% than below, in contrast to the previous reports where drinking was maintained at high concentrations of alcohol. While the animals will select alcohol in the face of a saccharin choice, they will not drink alcohol adulterated with quinine. We have failed to observe signs of dependence or withdrawal by these techniques and suggest that the original reports of these signs may have been a result of cellular damage caused by the long-term infusions. Additionally we have carried out extensive dose-response experiments with both salsolinol and THP. Doses of THP of 104 nmoles/day were inhibitory to alcohol drinking. We conclude that these compounds do shift these animals preference for alcohol relatively permanently, but not to the point of gross intoxication nor into the highly aversive range of alcohol concentration. We cannot confirm the reports that salsolinol or THP produce withdrawal symptoms when infused.

[3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN). Regional distribution and in vivo binding after acute and chronic drug treatment

The regional distribution and in vivo binding of the dopamine analog 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen (ADTN) was studied in the brain. The highest density of binding sites was in the striatum, with virtually no binding in the cerebellum. The binding of [3H]ADTN reflects an occupation of specific dopamine sites because the binding was diminished by the simultaneous administration of the dopamine antagonist haloperidol or the dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa). Chronic administration of haloperidol or L-dopa prior to assaying for in vivo binding resulted in an increase in the number of sites for [3H]ADTN which correlates to the increase observed in in vitro assays following long-term treatment with these agents. The subcellular distribution of in vivo labeled ADTN sites in the caudate nucleus indicate a high density of specific binding sites in the microsomal fraction, P3. Overall, these data demonstrate that the aminotetralins, such as ADTN, which bind with high affinity to the dopamine receptor in the caudate nucleus in vitro and in vivo, can provide precise information on the topography of this receptor.